536 related articles for article (PubMed ID: 27535749)
1. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Normando EM; Davis BM; De Groef L; Nizari S; Turner LA; Ravindran N; Pahlitzsch M; Brenton J; Malaguarnera G; Guo L; Somavarapu S; Cordeiro MF
Acta Neuropathol Commun; 2016 Aug; 4(1):86. PubMed ID: 27535749
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone.
Javed H; Azimullah S; Abul Khair SB; Ojha S; Haque ME
BMC Neurosci; 2016 Aug; 17(1):58. PubMed ID: 27549180
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats.
Teerapattarakan N; Benya-Aphikul H; Tansawat R; Wanakhachornkrai O; Tantisira MH; Rodsiri R
Phytomedicine; 2018 May; 44():65-73. PubMed ID: 29895494
[TBL] [Abstract][Full Text] [Related]
6. PPAR-γ: therapeutic prospects in Parkinson's disease.
Carta AR
Curr Drug Targets; 2013 Jun; 14(7):743-51. PubMed ID: 23469878
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
[TBL] [Abstract][Full Text] [Related]
8. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
10. Puerarin protects dopaminergic neurons in Parkinson's disease models.
Zhang X; Xiong J; Liu S; Wang L; Huang J; Liu L; Yang J; Zhang G; Guo K; Zhang Z; Wu P; Wang D; Lin Z; Xiong N; Wang T
Neuroscience; 2014 Nov; 280():88-98. PubMed ID: 25218963
[TBL] [Abstract][Full Text] [Related]
11. Imipramine and amitriptyline ameliorate the rotenone model of Parkinson's disease in rats.
Kandil EA; Abdelkader NF; El-Sayeh BM; Saleh S
Neuroscience; 2016 Sep; 332():26-37. PubMed ID: 27365173
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson's disease.
Parkhe A; Parekh P; Nalla LV; Sharma N; Sharma M; Gadepalli A; Kate A; Khairnar A
Neurosci Lett; 2020 Jan; 716():134652. PubMed ID: 31778768
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
14. Low Molecular Weight Sulfated Chitosan: Neuroprotective Effect on Rotenone-Induced In Vitro Parkinson's Disease.
Manigandan V; Nataraj J; Karthik R; Manivasagam T; Saravanan R; Thenmozhi AJ; Essa MM; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):505-515. PubMed ID: 30426393
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
Aksoy D; Solmaz V; Çavuşoğlu T; Meral A; Ateş U; Erbaş O
Am J Med Sci; 2017 Sep; 354(3):319-324. PubMed ID: 28918840
[TBL] [Abstract][Full Text] [Related]
16. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
17. Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease.
Kundu P; Das M; Tripathy K; Sahoo SK
ACS Chem Neurosci; 2016 Dec; 7(12):1658-1670. PubMed ID: 27642670
[TBL] [Abstract][Full Text] [Related]
18. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal MPTP drives retinal ganglion cell loss with oral nicotinamide treatment providing robust neuroprotection.
Rombaut A; Jovancevic D; Wong RC; Nicol A; Brautaset R; Finkelstein DI; Nguyen CTO; Tribble JR; Williams PA
Acta Neuropathol Commun; 2024 May; 12(1):79. PubMed ID: 38773545
[TBL] [Abstract][Full Text] [Related]
20. Naringin Exhibits Neuroprotection Against Rotenone-Induced Neurotoxicity in Experimental Rodents.
Garabadu D; Agrawal N
Neuromolecular Med; 2020 Jun; 22(2):314-330. PubMed ID: 31916219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
